title: [Diseases caused by human papillomavirus -- the possibilities and the public health advantages of prevention].
authors.forename: Nandor
authors.initials: N
authors.lastname: Acs
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Bata
authors.forename: David
authors.initials: D
authors.lastname: Danko
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Hernádi
authors.forename: Mihály
authors.initials: M
authors.lastname: Kálmán
authors.forename: László
authors.initials: L
authors.lastname: Kornya
authors.forename: Julianna
authors.initials: J
authors.lastname: Kovács
authors.forename: Gyula
authors.initials: G
authors.lastname: Mézáros
authors.forename: Márk Péter
authors.initials: MP
authors.lastname: Molnár
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Mór
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Novák
authors.forename: Gábor
authors.initials: G
authors.lastname: Sobel
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Szentirmay
authors.forename: László
authors.initials: L
authors.lastname: Takács
authors.forename: Tímea
authors.initials: T
authors.lastname: Tisza
mesh_terms: D052685:Alphapapillomavirus; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D003218:Condylomata Acuminata / Q000517:prevention & control / Q000821:virology; D017281:Cost of Illness; D004938:Esophageal Neoplasms / Q000517:prevention & control / Q000821:virology; D005260:Female; D005833:Genital Neoplasms, Female / Q000517:prevention & control / Q000821:virology; D005834:Genital Neoplasms, Male / Q000517:prevention & control / Q000821:virology; D014943:Global Health; D017048:Health Care Costs; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D008297:Male; D032541:Mass Vaccination; D008962:Models, Theoretical; D009369:Neoplasms / Q000191:economics / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D009959:Oropharyngeal Neoplasms / Q000517:prevention & control / Q000821:virology; D030361:Papillomavirus Infections / Q000150:complications* / Q000191:economics / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D011322:Primary Prevention; D011634:Public Health; D012141:Respiratory Tract Infections / Q000517:prevention & control / Q000821:virology; D055502:Secondary Prevention; D014626:Vaginal Smears
chemical_list: D019496:Cancer Vaccines; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18